Real-world studies (RWS) are crucial in clinical outcome evaluation of cancer patients (pts), however results are difficult to compare to randomized trials, mainly regarding time parameters, such as PSF, which is not the case in RWS. AMBRA is an observational study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve MBC pts receiving chemotherapy (CHT). One of the aims is the validation of TTC as a surrogate parameter of PFS. The present analysis is focused on the comparison between TTC and PFS of 1-line Paclitaxel + Bevacizumab (P+B) as an example of TTC in RWS.
Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study
Clara Natoli;
2018-01-01
Abstract
Real-world studies (RWS) are crucial in clinical outcome evaluation of cancer patients (pts), however results are difficult to compare to randomized trials, mainly regarding time parameters, such as PSF, which is not the case in RWS. AMBRA is an observational study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve MBC pts receiving chemotherapy (CHT). One of the aims is the validation of TTC as a surrogate parameter of PFS. The present analysis is focused on the comparison between TTC and PFS of 1-line Paclitaxel + Bevacizumab (P+B) as an example of TTC in RWS.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
